Calibr data bring switchable CAR Ts back into focus

With some of the first clinical evidence that a switchable CAR T cell may build on the safety and efficacy of traditional CAR T designs, a team from the Calibr drug discovery division of Scripps Research may be renewing interest in the therapeutic structure. 

The Calibr team, with support from partner AbbVie Inc. (NASDAQ:ABBV), reported at the CAR-TCR Summit 2022 that CD19-targeting CAR T cell therapy CLBR001 plus small molecule switch SWI019 led to objective responses in seven of nine B cell malignancy patients (78%), and complete responses in six (67%). Patients received a median of five prior lines of treatment, but the types of B cell malignancies were not reported. ...